AAV Gene Augmentation Therapy for CRB1-Associated Retinitis Pigmentosa

Research output: Contribution to journal/periodicalArticleScientificpeer-review

18 Citations (Scopus)


Mutations in the CRB1 gene account for around 10,000 persons with Leber congenital amaurosis (LCA) and 70,000 persons with retinitis pigmentosa (RP) worldwide. Therefore, the CRB1 gene is a key target in the fight against blindness. A proof-of-concept for an adeno-associated virus (AAV)-mediated CRB2 gene augmentation therapy for CRB1-RP was recently described. Preclinical studies using animal models such as knockout or mutant mice are crucial to obtain such proof-of-concept. In this chapter we describe a technique to deliver AAV vectors, into the murine retinas, via the subretinal route. We also present protocols to detect expression of the therapeutic protein by fluorescence immunohistochemistry and to perform histological studies using ultra-thin sections stained with toluidine blue. These techniques in combination with electroretinography and visual behavior tests are in principle sufficient to obtain proof-of-concept for new gene therapies.

Original languageEnglish
Pages (from-to)135-151
Number of pages17
JournalMethods in Molecular Biology
Publication statusPublished - 2018


  • Journal Article


Dive into the research topics of 'AAV Gene Augmentation Therapy for CRB1-Associated Retinitis Pigmentosa'. Together they form a unique fingerprint.

Cite this